Request Demo

Last update 23 Jan 2025

Infliximab

Last update 23 Jan 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Avakine, CenTNF, Infliximab (Genetical Recombination)

+ [8]

Target

TNF-α

Mechanism

TNF-α inhibitors(Tumor necrosis factor α inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesCardiovascular Diseases+ [7]

Active Indication

Mucocutaneous Lymph Node SyndromeBehcet's uveitisErythrodermic psoriasis+ [17]

Inactive Indication

Axial SpondyloarthritisBerylliosisCachexia+ [12]

Originator Organization

Janssen Global Services LLC

Active Organization

Mitsubishi Tanabe Pharma Corp.Janssen Biologics BV

Janssen Biotech, Inc.

+ [2]

Inactive Organization

Merck Sharp & Dohme Corp.

Nichi-Iko Pharmaceutical Co., Ltd.

Xian-Janssen Pharmaceutical Ltd.

+ [2]

Drug Highest PhaseApproved

First Approval Date

US (24 Aug 1998),

Crohn Disease

RegulationFast Track (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (JP)

Structure/Sequence

Sequence Code 69035L

Source: *****

Sequence Code 69038H

Source: *****

415

Clinical Trials associated with Infliximab

NCT06758024

/ Not yet recruitingNot ApplicableIIT

Multicentric Evaluation of a Strategy for Early Infliximab Optimization Among Adult Inflammatory Bowel Disease Patients

Infliximab (IFX) is a Food and Drug administration (FDA)-appoved monoclonal antibody medication targeting tumor necrosis factor (TNF) widely used in inflammatory bowel disease (IBD) to treat intestinal inflammation and improve patient's symptoms. Intravenous (iv) IFX is effective to treat hospitalized IBD patients with moderate-to-severe flares who fail iv corticosteroids (CS). However, about one-third of IBD patients do not respond to this medications and a half will loss the response after an initial response. Researchers have shown that most of these phenomena occur due to low IFX concentrations sometimes accompanied by the development of anti-drug antiboides (ADA) againts IFX.
Blood concentrations of IFX are widely variable among IBD patients despite receiving the same weight-based dose. Several patient factors including laboratory parameters and severity of intestinal inflammation influence the way an individual's body proccesses and eliminate this type of medications. Dashboard software systems can take into account patient characteristics and IFX concentrations to modelate and facilitate dosing of IFX. By using pharmacokinetics (PK) models specifically developed to facilitate IFX dosing, these softwares can provide and recommend multiple dosing regimes to help the clinicians to select the appropriate dose to achieve target and optimal IFX concentrations.
The goal of this clinical trial is to learn if early measuring of IFX blood concentrations and dashboard-guided IFX dose adjustment in Chilean IBD patients starting IFX, increases the proportion of patients with optimal IFX levels and improves patient outcomes. Researchers will measure IFX concentrations before the second (week 2) and third dose (week 6) in a prospectively collected individual patient cohort and this information along with clinical data will be analyzed with a dashboard software system and multiple dosing regime options will be provide to the attending clinicians to facilitate the selection of the next IFX weight-based dose and interval of infusions. This group will be compared with IBD patients with standard of dosing where attending clinicians make the dosing decisions based on clinical parameters. We will analyze if IBD patients in the dashboard-guided dosing arm achieve a higher proportion of optimal IFX concentrations at week 14 of treatment, develop ADA less frequently and improve clinical outcomes compared with standard dosing group.
Participants will be asked to:
* Provide clinical data about their disease and other conditions
* Provide blood samples at enrollment and before each IFX infusion (IFN) during one year
* Maintain regular clinical assessments every 3 months for one year

Start Date01 Jan 2025

Sponsor / Collaborator

Pontificia Universidad Católica de Chile

[+1]

NCT06601595

/ Not yet recruitingNot ApplicableIIT

Spondyloarthropathy in Inflammatory Bowel Disease Patients and Evaluation of Its Response to TNF Inhibitors in Assiut University Hospital

Prevelance of axial spondylosis arthritis in inflammatory bowel disease and its RESPONSE to tumour necrosis factor (TNF) inhibitors TREATMENT

Start Date01 Oct 2024

Sponsor / Collaborator

Assiut University

NCT06614387

/ Not yet recruitingPhase 3IIT

Assessment of Safety and Efficacy of Vedolizumab in Pediatric Uclerative Colitis in Comparison With Standard Biological Therapy With Infliximab

This is a multicenter, double-blind, randomized study to compare the safety, effectiveness and immunogenicity (antibodies against drug) of two biological drugs administered intravenously - vedolizumab (a drug not registered in pediatric patients) and infliximab (used as standard therapy), in pediatric patients with UC aged 6-18 years.
Before enrollment to the study, informed consent must be obtained from the participant's legal guardian and, additionally, from the participant aged >16 years before any procedures are performed.

Start Date01 Oct 2024

Sponsor / Collaborator

$Instytut \"Pomnik - Centrum Zdrowia Dziecka\"$ Instytut \"Pomnik - Centrum Zdrowia Dziecka\"

100 Clinical Results associated with Infliximab

100 Translational Medicine associated with Infliximab

100 Patents (Medical) associated with Infliximab

15,217

Literatures (Medical) associated with Infliximab

31 Dec 2025·ANNALS OF MEDICINE

Tumour necrosis factor inhibitors in Ulcerative colitis: real-world data on Therapeutic drug monitoring and evaluation of current treatment targets (STRIDE II)

Article

Author: Lundekvam, Jonas Andre ; Småstuen, Milada Cvancarova ; Medhus, Asle Wilhelm ; Warren, David J. ; Høivik, Marte Lie ; Bolstad, Nils ; Anisdahl, Karoline

BACKGROUND:

The benefit of therapeutic drug monitoring (TDM) and implementation of recommendations from the Selection of Therapeutic Targets in Inflammatory Bowel Disease (IBD, STRIDE) are discussed in the IBD community. We report real-world data in ulcerative colitis patients receiving first-line tumour necrosis factor inhibitor (TNFi) treatment followed by TDM, and assess how implementation of the STRIDE II recommendations might affect clinical practice.

METHODS:

Adult, biologically naïve UC patients starting TNFi between 2014 and 2021 at Oslo University Hospital were included in a medical chart review study, and data were collected at three and twelve months after the start of treatment. Target serum drug levels were defined as ≥7.5 mg/L for adalimumab and ≥5 mg/L for infliximab.

RESULTS:

Of 141 included patients, 36% were in clinical and biochemical (combined) remission after twelve months. Among 102 treatment persistent patients, 54% were in combined remission after twelve months. Target drug level at three months was associated with clinical remission at twelve months (OR = 2.97, 95% CI [1.24-7.12]) and biochemical remission at twelve months (OR = 2.64, 95% CI [1.03-6.77]). In total, 56% of recorded dosage adjustments were related only to serum drug levels.

CONCLUSIONS:

Combined remission rates at twelve months for treatment persistent patients suggest that 46% should have been considered for a change of treatment according to the STRIDE II recommendations. A majority of dosage adjustments were made proactively. Target drug level at three months was associated with remission at twelve months and supports the use of proactive TDM.

01 Dec 2025·Current Rheumatology Reports

An Update on Kawasaki Disease

Review

Author: Goel, Anurag Ratan ; Yalcindag, Ali

PURPOSE:

To summarize advances in research on the epidemiology, pathogenesis, diagnosis, and treatment of Kawasaki Disease (KD), a systemic inflammatory illness of unknown etiology that affects children globally.

RECENT FINDINGS:

The epidemiology of KD was affected by the COVID-19 pandemic and advances in molecular immunology and machine learning have enabled research into its pathogenesis. There is ongoing research into agents that can be used to intensify initial treatment and accumulating evidence supporting the use of certain rescue regimens for refractory disease over others. There is promise surrounding a new coronary artery aneurysm prediction model. Research into the post-acute morbidity of KD continues. The COVID-19 pandemic temporarily reduced the incidence of KD. The NLRP3 inflammasome plays a key role in KD pathogenesis. Intensified initial treatment benefits high-risk patients, yet no intensification regimen shows superiority over another. Corticosteroids, infliximab, or combination therapy with IVIg plus another agent may be superior rescue regimens compared to IVIg alone for refractory KD. The Son score, developed in North America, predicted coronary artery lesions in Japanese and Italian cohorts. Patients with a history of KD may carry long-term physical and emotional burdens that persist into adulthood yet appear to have typical neurocognitive development. Successful transition to adult healthcare presents a challenge.

01 Apr 2025·DEN open

Colitis in a patient with familial Mediterranean fever: Is it Crohn's disease or ulcerative colitis?

Article

Author: Shimodate, Yuichi ; Nishimura, Naoyuki ; Takezawa, Rio ; Matsueda, Kazuhiro ; Mouri, Hirokazu ; Hoshi, Ayano ; Matsumoto, Takayuki ; Mizuno, Motowo ; Gotoda, Tatsuhiro

Abstract:

A 24‐year‐old woman was referred to our hospital with joint pain, fever, abdominal pain, and diarrhea. A colonoscopy revealed longitudinal ulcers with a cobblestone appearance throughout the entire colon, suggestive of Crohn's disease. However, treatment with 5‐aminosalicylic acid, azathioprine, and infliximab failed to achieve clinical remission. A colonoscopy 5 months later revealed a diffusely spreading granular mucosa without visible vasculature, compatible with active ulcerative colitis. Based on these serial changes in colonic lesions, we tested the patient for MEFV gene mutations and found variants E148Q and L110P in exon 2. Administration of colchicine resulted in complete clinical remission. Our experience suggests that drastic changes in the features of colonic inflammation may be a clue to the diagnosis of enterocolitis associated with familial Mediterranean fever.

169

News (Medical) associated with Infliximab

15 Jan 2025

·www.businesswire.com

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

BALTIMORE--( BUSINESS WIRE )--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has achieved a key safety data milestone supporting expanded and longer-term clinical studies of its novel TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in multiple indications. The Company successfully completed an FDA-recommended study of isomyosamine that demonstrated clinical safety throughout 13 weeks of treatment at all dose levels evaluated. “Positive data from this milestone study confirms isomyosamine’s historically strong safety profile and enables us to extend the duration of future clinical trials,” said Mitchell Glass, M.D., President and Chief Medical Officer of TNFA. “We believe we are fully equipped to advance our comprehensive isomyosamine platform in a longer-term clinical trial in sarcopenia and future studies in multiple conditions associated with immunometabolic dysregulation.” Trials, Indications, and Markets Sarcopenia/frailty: TNFA plans to launch a Phase 2b clinical trial of isomyosamine’s efficacy in sarcopenia early in the first quarter of 2025. The study will further explore the drug’s efficacy in sarcopenia/frailty following statistically significant positive results from an earlier Phase 2 clinical study. The sarcopenia treatment market is estimated to be $3.07 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 4.48% and is estimated to reach $4.02 billion by 2029. 1 GLP-1 muscle loss: the Company recently announced a planned trial of isomyosamine as a treatment for GLP-1-induced sarcopenia and frailty. The fully funded study is expected to evaluate TNF-α levels in patients receiving GLP-1 agonist Wegovy or Ozempic who show signals for increased inflammation associated with sarcopenia. Currently valued at $49.3 billion, the GLP-1 agonist market is projected to reach $105 billion by 2029, growing at an expected CAGR of 19.2% from 2023 to 2029. 2 According to the Centers for Disease Control and Prevention, obesity costs the U.S. healthcare system nearly $173 billion annually. 3 TNF inhibitor drug category: the global market value for TNF inhibitors was estimated to be $39.7 billion in 2024. Growing at an expected CAGR of 3.6% for the next five years, the TNF inhibitor market is expected to reach $47.3 billion by 2029. 4 About Isomyosamine Isomyosamine (MYMD-1®) is a novel plant alkaloid small molecule shown to regulate the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines including TNF-alpha (TNF-α), an immune cell signaling protein and inflammatory cytokine responsible for inducing and maintaining the inflammatory process. TNF-α is located upstream of a cascade of molecular signals that induces inflammation and helps activate the process of aging. Many in vivo and in vitro studies have shown that TNF-α plays a causative role in the pathogenesis of various age-related diseases. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit www.tnfpharma.com . Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would’’ and other similar expressions are intended to identify these forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the Company’s ability to launch and the timing of the Company’s planned trial of MYMD-1 as a treatment for GLP-1-induced sarcopenia and frailty. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company’s ability to maintain compliance with the Nasdaq Stock Market’s listing standards; the timing of, and the Company’s ability to, obtain and maintain regulatory approvals for clinical trials of the Company’s pharmaceutical candidates; the timing and results of the Company’s planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company’s ability to retain and attract senior management and other key employees; the Company’s ability to quickly and effectively respond to new technological developments; and the Company’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company’s proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed by the Company on April 1, 2024, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. ________________________________ 1 Mordor Intelligence, Sarcopenia Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029) 2 Global Data , March 2024 3 Centers for Disease Control and Prevention (CDC), About Obesity , January 2024 4 Mordor Intelligence, TNF Inhibitors Market Size (2024 - 2029)

Phase 2Clinical Result

31 Dec 2024

·www.echemi.com

Johnson & Johnson Invests $1.2 Billion to Acquire Global Rights for STAT6 Inhibitor

Recently, Johnson & Johnson (J&J) announced an agreement with Kaken Pharmaceutical of Japan to acquire the global exclusive rights (excluding Japan) to KP-723, a preclinical STAT6 inhibitor. Under the agreement, J&J will pay $30 million upfront, with potential milestone payments of up to $1.2175 billion, and will receive single-digit to low double-digit percentage royalties on future sales of the drug. Kaken Pharmaceutical plans to initiate Phase 1 clinical trials for atopic dermatitis (AD) next year and intends to explore its application in other Th2-mediated diseases, such as asthma. J&J will be responsible for the global clinical development and commercialization of the drug. The significant investment in STAT6 inhibitors stems from their critical role in the JAK/STAT signaling pathway. STAT6, as a downstream target, primarily responds to the stimulation of cytokines IL-4 and IL-13, promoting the expression of Th2-related genes and enhancing immune responses. In diseases such as asthma and AD, the abnormal activation of STAT6 can exacerbate inflammation and worsen disease progression. STAT6 represents a "first-in-class" target for developing novel oral therapies against these diseases. However, as a transcription factor, STAT6 lacks deep binding pockets, making it challenging to develop drugs against. While early attempts at STAT6 inhibitors for autoimmune diseases often failed due to insufficient affinity, the application of PROTAC technology has provided a promising solution. Currently, the most advanced STAT6 inhibitor project is Kymera Therapeutics' KT-621, whose IND application was approved by the U.S. FDA in October this year. In vitro models have shown that KT-621 can completely block the IL-4/IL-13 pathway by degrading STAT6, with efficacy comparable to or better than the monoclonal antibody Dupilumab. Moreover, KT-621 has demonstrated nearly complete degradation of STAT6 at low oral doses and has shown good tolerability in multiple preclinical toxicity studies. Meanwhile, Sanofi is also actively investing in STAT6 inhibitors to protect its Dupilumab market share. Through partnerships with Nurix and Recludix, Sanofi is developing STAT6 protein degraders and small-molecule inhibitors, both in the preclinical stage. The STAT6 inhibitor space has become a hotspot for heavy investment by multinational pharmaceutical companies in the autoimmune field. According to Frost & Sullivan, the global autoimmune drug market is expected to reach $176 billion by 2030, with a compound annual growth rate of 3.6% from 2022 to 2030. In China, the market size is projected to reach $23.1 billion by 2030, with the share of biologics increasing from 32.9% in 2021 to 71.8% by 2030, making it a major growth driver in the global market. J&J has a rich history and extensive product portfolio in the autoimmune drug space, with flagship products like Remicade (Infliximab), Stelara (Ustekinumab), Tremfya (Guselkumab), and Simponi/Simponi Aria (Golimumab). Despite the declining sales of Remicade due to competition from biosimilars (2023 revenue: $1.839 billion), Stelara's 2023 sales exceeded $10 billion for the first time, reaching $10.858 billion, making it the core pillar of J&J's pharmaceutical business. However, Stelara faces patent expiration, with its U.S. patent expiring in September 2023, leading to a 6.6% revenue decline in Q3 2024 to $2.6 billion. Nevertheless, Tremfya, approved for treating psoriasis, received additional approval on September 11 this year for moderate-to-severe active ulcerative colitis (UC), showing potential to succeed Stelara. To solidify its leadership in the autoimmune field, J&J continues to aggressively pursue new products to replace its existing lineup. In the AD field, J&J has made two acquisitions this year, both targeting bispecific antibodies for AD treatment. It acquired Proteologix for $850 million, securing candidates like PX128 and PX130. PX128, a bispecific antibody targeting IL-13/TSLP, is about to enter Phase 1 clinical development, while PX130, targeting IL-13/IL-22, is in preclinical development for moderate-to-severe AD. J&J also entered an agreement with Numab Therapeutics to acquire Yellow Jersey Therapeutics for approximately $1.25 billion, gaining global rights to NM26, a bispecific antibody targeting IL-4Rα and IL-31 for AD. NM26 is currently in Phase 1 trials and about to enter Phase 2 development. In the psoriasis space, J&J has consistently led the way, offering products like Infliximab, Golimumab, Ustekinumab, and Guselkumab. The recent introduction of Icotrokinra (JNJ-2113), an oral IL-23R-targeting peptide licensed from Protagonist, has achieved positive results in pivotal Phase 3 trials for plaque psoriasis, marking the potential launch of the world's first selective oral IL-23 receptor inhibitor, further cementing J&J’s dominance in this space. Additionally, Nipocalimab, an FcRn-targeting monoclonal antibody acquired for $6.5 billion from Momenta, has shown breakthrough potential across various autoimmune diseases. In August 2023, J&J submitted a BLA to the FDA for treating generalized myasthenia gravis (gMG) and received BTD designation for treating Sjögren's syndrome based on the DAHLIAS Phase 2 study. Nipocalimab is projected to have a peak sales potential exceeding $5 billion, despite existing competition from Argenx and UCB in the FcRn space. As a leader in autoimmune disease therapies, J&J faces challenges such as patent expirations for key products and head-to-head competition from first-in-class rivals. However, its proactive acquisitions and investments reflect its determination to open new pathways in the autoimmune space. Whether J&J can maintain its dominant position in the coming decade remains highly anticipated.

Phase 1License out/inPhase 3Drug ApprovalBreakthrough Therapy

27 Dec 2024

·www.drugs.com

Data Suggests TNF Inhibitors Help Prevent Serious Complications in Children with Crohn's Disease

FRIDAY, Dec. 27, 2024 A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn’s disease . A new study published recently in the journal Gut shows children with Crohn's who were prescribed anti-TNF (tumor necrosis factor) drugs following their diagnosis had an 82% lower risk of anal fistulas, or tunnels that develop from inside the anus to the skin outside. These tunnels appear as open draining sores near the anus, and increase a child’s risk of infections or organ damage, researchers said. About 70% of kids who develop an anal fistula require at least one surgical procedure, researchers said. This frequently involves fitting the child with a colostomy bag. “If we can prevent these disease complications, that’s way better than trying to address them once they develop, because they’re so hard to treat,” lead researcher Dr. Jeremy Adler , a clinical professor of pediatric gastroenterology with the University of Michigan, said in a news release. About 40,000 children in the U.S. suffer from Crohn’s disease, a chronic inflammatory disease of the gut that causes diarrhea, cramping and pain. Of those children, about one in three will develop anal fistulas, researchers said. For the study, researchers tracked more than 900 children newly diagnosed with Crohn’s. They found that prescribing anti-TNF drugs like infliximab and adalimumab from the outset significantly decreased a child’s risk of anal fistulas. These drugs block TNF, a substance that causes inflammation. This was particularly true for children who had already developed large skin tags, ulcers or fissures near their anus. The presence of these lesions quadruples a child’s odds of anal fissures, study results show. But for those kids, anti-TNF drugs decreased their risk of anal fistulas by 93%, researchers found. Anti-TNF drugs are pricier than other anti-inflammatory drugs used to treat Crohn’s like azathioprine and methotrexate , researchers said. However, these results show that anti-TNF drugs might be worth the added cost, if they can help kids avoid anal fistulas that are even more expensive to treat, Adler said. “For the insurance companies, you prevent the fistulas and all the downstream complications those cost,” Adler said. “For the physician, it shows this is really the more efficacious treatment.” “For the families, it’s a question of which drug. And this group of medicines is so effective at preventing complications," Adler concluded. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with Infliximab

External Link

KEGG	Wiki	ATC	Drug Bank
D02598	Infliximab	L04AB02	DB00065

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Mucocutaneous Lymph Node Syndrome	JP	Mitsubishi Tanabe Pharma Corp.	21 Dec 2015
Behcet's uveitis	JP	Mitsubishi Tanabe Pharma Corp.	26 Jan 2007
Erythrodermic psoriasis	JP	Mitsubishi Tanabe Pharma Corp.	17 Jan 2002
Psoriasis vulgaris	JP	Mitsubishi Tanabe Pharma Corp.	17 Jan 2002
Pustular psoriasis	JP	Mitsubishi Tanabe Pharma Corp.	17 Jan 2002
Ankylosing Spondylitis	EU	Janssen Biologics BV	13 Aug 1999
Ankylosing Spondylitis	IS	Janssen Biologics BV	13 Aug 1999
Ankylosing Spondylitis	LI	Janssen Biologics BV	13 Aug 1999
Ankylosing Spondylitis	NO	Janssen Biologics BV	13 Aug 1999
Arthritis, Psoriatic	EU	Janssen Biologics BV	13 Aug 1999
Arthritis, Psoriatic	IS	Janssen Biologics BV	13 Aug 1999
Arthritis, Psoriatic	LI	Janssen Biologics BV	13 Aug 1999
Arthritis, Psoriatic	NO	Janssen Biologics BV	13 Aug 1999
Colitis, Ulcerative	EU	Janssen Biologics BV	13 Aug 1999
Colitis, Ulcerative	IS	Janssen Biologics BV	13 Aug 1999
Colitis, Ulcerative	LI	Janssen Biologics BV	13 Aug 1999
Colitis, Ulcerative	NO	Janssen Biologics BV	13 Aug 1999
Crohn's disease, active moderate	EU	Janssen Biologics BV	13 Aug 1999
Crohn's disease, active moderate	IS	Janssen Biologics BV	13 Aug 1999
Crohn's disease, active moderate	LI	Janssen Biologics BV	13 Aug 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Behcet Syndrome	Phase 3	JP	Mitsubishi Tanabe Pharma Corp.	01 Jan 2012
Axial Spondyloarthritis	Phase 3	-	Merck Sharp & Dohme Corp.	01 Sep 2009
Polymyalgia Rheumatica	Phase 3	ES	Schering-Plough Corp.	01 Jun 2007
Myositis	Phase 3	-	Schering-Plough Corp.	05 Mar 2007
Pustulosis of Palms and Soles	Phase 3	CA	Schering-Plough Corp.	01 Mar 2007
Hepatitis C, Chronic	Phase 3	-	Merck Sharp & Dohme Corp.	18 Jul 2005
Sarcoidosis	Phase 3	-	Centocor, Inc.	01 Oct 2003
Parapsoriasis	Phase 3	-	Centocor, Inc.	01 Jan 2003
Pulmonary Disease, Chronic Obstructive	Phase 3	-	Centocor, Inc.	01 Dec 2002
Spondylarthropathies	Phase 3	MX	Schering-Plough Corp.	01 Jun 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02770040 (PREDICT-UC, Pubmed \| Lancet Gastroenterol Hepatol)	Phase 4	Colitis, Ulcerative	138	10 mg/kg infliximab	floestrdjb(mdcviipisd) = cmwrvoehjy yovnxnxuhd (kgusaowspc ) View more	Positive	01 Sep 2024
				5 mg/kg infliximab	floestrdjb(mdcviipisd) = oblmlpraxh yovnxnxuhd (kgusaowspc ) View more
NCT05340764 (CTgov)	Phase 4	Inflammatory Bowel Diseases	96	Infliximab (2-hour Infusion of Infliximab)	idhqrrzcdk(bscthuknso) = corazbnzec apzespmwko (syreuhjpuo, halkmgbdin - kyrbtggujf) View more	-	29 Aug 2024
				Infliximab (1-hour Infusion of Infliximab)	idhqrrzcdk(bscthuknso) = smyzppcjyj apzespmwko (syreuhjpuo, jvxrbnqedu - gptqhfttsc) View more
NCT02251041 (CAPITL, CTgov)	Phase 2	Reperfusion Injury	143	C1-Inhibitor+Epoprostenol+Infliximab+Melatonin+Alfa-tocopherol+Human recombinant erythropoietin+Glutathione	hfwqgraivw(gjgcmvrxtb) = jhlnohgyzp eviorvqeot (tydnaeckcv, qbdzmmwucd - fwwdnchqlt) View more	-	23 Aug 2024
EULAR2024 Manual	Not Applicable	Behcet Syndrome TNF-α	77	Infliximab	vaioosxzul(clgsmrrxmx) = fcobtjmdkt roahtefwyb (vjpukewhpf ) View more	Positive	05 Jun 2024
EULAR2024 Manual	Not Applicable	Sarcoidosis Third line	36	Infliximab 5mg/kg	fawirrcuvb(ssjseecxgq) = 77% of patients remained on treatment, 13.8% experienced non-severe adverse reactions, and only the 2.7% developed infective complications (TB). zjegodsmyi (pipvsoqryw )	Positive	05 Jun 2024
EULAR2024 Manual	Not Applicable	Sarcoidosis ACE \| Il2Ra levels	18	Infliximab therapy	mjbwtqskmy(emrwnthbjd) = cvzqlitnya daowwylwea (aeqxtydzqt ) View more	Positive	05 Jun 2024
EULAR2024 Manual	Not Applicable	Neurosarcoidosis Third line	40	Cyclophosphamide	qxqxqswceh(ueehixwzyj) = fumbbovpbb vfpoxicaui (fyekjyjygs ) View more	Positive	05 Jun 2024
				Infliximab	qxqxqswceh(ueehixwzyj) = gqwcyxqbwt vfpoxicaui (fyekjyjygs ) View more
EULAR2024	Phase 2	Behcet Syndrome	52	Infliximab	fjgpshxsbp(qjiijaiulm) = uitrvqsuew gkgwodwmyg (dpjnfqkfcp ) View more	Positive	05 Jun 2024
				Cyclophosphamide	fjgpshxsbp(qjiijaiulm) = eriolnljeh gkgwodwmyg (dpjnfqkfcp ) View more
EULAR2024	Not Applicable	IL-17A	135	Adalimumab (ADA)	zenwwdjhfd(pdybpcafcc) = lgsmkvngzq pikbspmazf (gfdixppnkx )	Positive	05 Jun 2024
				Infliximab (IFX)	zenwwdjhfd(pdybpcafcc) = jzaizyxnwi pikbspmazf (gfdixppnkx )
EULAR2024	Not Applicable	Rheumatoid Arthritis	-	Biologic and targeted synthetic DMARDs	mvxbfbpknj(tolijcwumh) = jfmapqglzr nsplcitpjh (ngugcsqxmt ) View more	-	05 Jun 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis